title: [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].
abstract: Immunotherapy is generally associated with an increased risk for the development of infections. Due to the continuously expanding spectrum of new and potent immunotherapy treatment options for multiple sclerosis (MS), this article describes the currently known risks for treatment-related infections and the current recommendations for prevention of corresponding problems with drugs used in treatment strategies for MS and their mechanisms of action. The new treatment options in particular are linked to specific and severe infections; therefore, intensive and long-lasting monitoring is required before, during and after treatment and multidisciplinary surveillance of patients is needed. This article gives a detailed review of drug-specific red flags and current recommendations for the prophylaxis of infections associated with treatment of relapsing-remitting MS and when using self-injectable and oral disease-modifying immunotherapeutic drugs.
authors.affiliation: Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Gehlsheimer Str. 20, 18147, Rostock, Deutschland, alexander.winkelmann@med.uni-rostock.de.
authors.forename: A
authors.initials: A
authors.lastname: Winkelmann
authors.forename: M
authors.initials: M
authors.lastname: Löbermann
authors.forename: E C
authors.initials: EC
authors.lastname: Reisinger
authors.forename: H-P
authors.initials: HP
authors.lastname: Hartung
authors.forename: U K
authors.initials: UK
authors.lastname: Zettl
mesh_terms: D000284:Administration, Oral; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use*; D007167:Immunotherapy / Q000009:adverse effects*; D017053:Infection Control / Q000379:methods*; D007239:Infections / Q000139:chemically induced; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D012646:Self Administration / Q000009:adverse effects / Q000379:methods
chemical_list: D007155:Immunologic Factors